Highlights

  • a2 Milk has secured SAMR approval to transition two China infant formula registrations to the a2™ brand.
  • The approval completes a key requirement tied to the acquisition of the a2 Pokeno manufacturing facility.
  • The company expects to launch the new China-labelled products later in 2026 and plans to consider a $300 million special dividend.

Overview

The a2 Milk Company (NZX:ATM) has received approval from China’s State Administration for Market Regulation (SAMR) to convert two infant milk formula registrations acquired through the a2 Pokeno facility into a2™ branded products. The milestone finalizes a critical regulatory step linked to the acquisition and strengthens the company’s strategy to expand its presence in the Chinese infant nutrition market. The company expects product launches later this year while maintaining previously communicated financial expectations.

How Does SAMR Approval Strengthen a2 Milk’s China Growth Strategy?

The regulatory approval provides a2 Milk with the ability to market the acquired infant formula registrations under its own brand in China. This enhances the company’s market access and supports product innovation within its core infant nutrition business. Management believes the approval will contribute to long-term growth by expanding manufacturing capabilities, increasing brand value, and improving margins through greater control of production and supply chain operations.

What Does the Approval Mean for the Pokeno Acquisition and Shareholders?

With all required regulatory approvals now secured, a2 Milk can no longer unwind its acquisition of the a2 Pokeno facility. The company stated that there is no change to the expected launch timeline or financial benefits associated with the acquisition. Following the approval, the Board is expected to meet soon to consider declaring a fully franked and unimputed special dividend of $300 million, with further details to be announced separately.

FAQs

Q: Why did a2 Milk receive SAMR approval?
A: The approval allows a2 Milk to transition two China infant formula registrations to a2™ branded products.

Q: What does the approval mean for the Pokeno facility acquisition?
A: It completes the final regulatory requirement, making the acquisition fully effective and no longer reversible.

Q: Will a2 Milk pay a special dividend?
A: The company expects its Board to convene soon with the intention of declaring a $300 million special dividend.